Additional Proxy Soliciting Materials (definitive) (defa14a)
2020年2月20日 - 2:11AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a)
of the Securities
Exchange Act of 1934
Filed by the Registrant x
Filed by a party other than the Registrant ¨
Check the appropriate box:
|
¨
|
Preliminary proxy statement
|
|
¨
|
Confidential, For use of the Commission only (as permitted
by Rule 14a-6(e)(2))
|
|
¨
|
Definitive proxy statement
|
|
x
|
Definitive additional materials
|
|
¨
|
Soliciting material pursuant to Rule 14a-11(c) or
Rule 14a-12
|
Titan Pharmaceuticals, Inc.
(Name of Registrant as Specified in Its
Charter)
(Name of Person(s) Filing Proxy Statement,
if Other Than the Registrant)
Payment of filing fee (Check the appropriate box):
|
¨
|
Fee computed on table below per Exchange Act Rules 14a-6(i)
(1) and 0-11.
|
|
(1)
|
Title of each class of securities to which transaction
applies:
|
|
|
|
|
(2)
|
Aggregate number of securities to which transaction
applies:
|
|
|
|
|
(3)
|
Per unit price or other underlying value of transaction
computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it
was determined):
|
|
|
|
|
(4)
|
Proposed maximum aggregate value of transaction:
|
|
|
|
|
¨
|
Fee paid previously with preliminary materials:
|
|
¨
|
Check box if any part of the fee is offset as provided
by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous
filing by registration statement number, or the form or schedule and the date of its filing.
|
|
(1)
|
Amount previously paid:
|
|
|
|
|
(2)
|
Form, Schedule or Registration Statement No.:
|
|
|
|
February 19, 2020
**** URGENT REMINDER ****
**** TIME SENSITIVE ****
Dear Fellow Titan Pharmaceuticals Stockholder:
As of the date of this letter, we still
have not received your vote for the Special Meeting of Stockholders of Titan Pharmaceuticals, Inc., which is scheduled to be held
on March 2, 2020.
YOUR VOTE IS IMPORTANT PLEASE
VOTE TODAY!
Your Board of Directors strongly recommends
that you vote your shares FOR the Reverse Stock Split proposal.
A favorable vote facilitates our ability
to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. Just as important,
it also provides requisite authorized shares of the company to complete any value creating potential business mergers or product
acquisitions that we might wish to pursue in the future, as well as raise additional funds, as needed, to finance these activities
and our ongoing operations. This proposal requires a majority of the outstanding shares of Titan Pharmaceuticals common stock voting
in favor in order to pass, so every vote is important.
The independent proxy advisory firms
Institutional Shareholder Services Inc. and Glass Lewis & Co. have reviewed the proxy statement and recommend that stockholders
vote FOR this proposal.
WE URGE YOU TO VOTE IN
FAVOR OF THE PROPOSAL
Instructions on how to vote your shares over the telephone or
Internet are enclosed with this letter. Alternatively, you may sign and return the enclosed voting form in the envelope provided.
If you have questions or need help voting your shares,
please call our proxy solicitation firm, Morrow Sodali LLC, at 800-662-5200
Thank you for your investment in Titan
Pharmaceuticals, Inc. and taking the time to vote your shares.
Marc Rubin, M.D.
Executive Chairman
400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080 Tel. (650)244-4990 Fax (650)244-4956
|
Titan Pharmaceuticals (PK) (USOTC:TTNPW)
過去 株価チャート
から 11 2024 まで 12 2024
Titan Pharmaceuticals (PK) (USOTC:TTNPW)
過去 株価チャート
から 12 2023 まで 12 2024